The estimated Net Worth of Rachid Izzar is at least $1.99 Million dollars as of 16 February 2024. Rachid Izzar owns over 2,017 units of Biogen Inc stock worth over $1,993,687 and over the last 3 years Rachid sold BIIB stock worth over $0.
Rachid has made over 11 trades of the Biogen Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Rachid exercised 2,017 units of BIIB stock worth $401,565 on 16 February 2024.
The largest trade Rachid's ever made was exercising 2,043 units of Biogen Inc stock on 7 February 2024 worth over $406,741. On average, Rachid trades about 823 units every 54 days since 2021. As of 16 February 2024 Rachid still owns at least 10,014 units of Biogen Inc stock.
You can see the complete history of Rachid Izzar stock trades at the bottom of the page.
Over the last 21 years, insiders at Biogen Inc have traded over $166,883,156 worth of Biogen Inc stock and bought 665,319 units worth $183,001,783 . The most active insiders traders include Adam Koppel, Alexander J Denner, and Stelios Papadopoulos. On average, Biogen Inc executives and independent directors trade stock every 10 days with the average trade being worth of $2,343,090. The most recent stock trade was executed by Priya Singhal on 30 August 2024, trading 1,668 units of BIIB stock currently worth $332,082.
through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili
Biogen Inc executives and other stock owners filed with the SEC include: